Neurohormonal Upregulation in Heart Failure

Heart Failure Clinics

Volumn 1, Issue 1, 2005, Pages 1-9

  Wilson Tang, W H ^a,b   Francis, Gary S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; EPLERENONE; METOPROLOL; SPIRONOLACTONE; TEZOSENTAN; TOLVAPTAN; VALSARTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ADRENERGIC SYSTEM; AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DOWN REGULATION; ENZYME ACTIVITY; HEART FAILURE; HEART PERFUSION; HOMEOSTASIS; HORMONE ACTION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE; UPREGULATION;

ADRENERGIC FIBERS; ENDOTHELINS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDES; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM; VASOPRESSINS;

EID: 33646005799     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2004.11.002     Document Type: Review

References (73)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20 (1992) 248-254
2. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 (2004) 292-299
3. Chidsey C.A., Braunwald E., and Morrow A.G. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39 (1965) 442-451
4. Eisenhofer G., Friberg P., Rundqvist B., et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93 (1996) 1667-1676
5. Lambert G.W., Kaye D.M., Lefkovits J., et al. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation 92 (1995) 1813-1818
6. Meredith I.T., Eisenhofer G., Lambert G.W., et al. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 88 (1993) 136-145
7. Bristow M.R., Hershberger R.E., Port J.D., et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82 (1990) 112-125
8. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
9. Kaye D.M., Lefkovits J., Jennings G.L., et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26 (1995) 1257-1263
10. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 (1990) 1724-1729
11. Gupta R., Tang W.H., and Young J.B. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J 147 (2004) 79-83
12. Olivari M.T., Levine T.B., and Cohn J.N. Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 2 (1983) 411-417
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
14. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 9169 (1999) 2001-2007
15. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
16. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
17. Tang W.H., Militello M., and Francis G.S. In heart failure, all beta-blockers are not necessarily equal. Cleve Clin J Med 70 (2003) 1081-1087
18. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
19. Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 6 (2004) 539-545
20. Tang W.H., Vagelos R.H., Yee Y.G., et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 39 (2002) 70-78
21. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
22. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
23. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
24. Williams J.S., and Williams G.H. 50th anniversary of aldosterone. J Clin Endocrinol Metab 88 (2003) 2364-2372
25. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
26. Macdonald J.E., Kennedy N., and Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90 (2004) 765-770
27. Schafer A., Fraccarollo D., Hildemann S.K., et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 58 (2003) 655-662
28. Cohn J.N., Anand I.S., Latini R., et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 108 (2003) 1306-1309
29. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
30. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102 (2000) 2700-2706
31. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
32. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
33. Goldsmith S.R. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 8 (2002) 251-256
34. Lee C.R., Watkins M.L., Patterson J.H., et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
35. Benedict C.R., Johnstone D.E., Weiner D.H., et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 23 (1994) 1410-1420
36. Schrier R.W., Cadnapaphornchai M.A., and Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis 3 (2001) 210-214
37. Francis G.S., and Tang W.H. Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?. JAMA 291 (2004) 2017-2018
38. Udelson J.E., Smith W.B., Hendrix G.H., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
39. Van Kerckhoven R., Lankhuizen I., van Veghel R., et al. Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats. Eur J Pharmacol 449 (2002) 135-141
40. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
41. Gheorghiade M., Niazi I., Ouyang J., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
42. Costello-Boerrigter L.C., Boerrigter G., and Burnett Jr. J.C. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am 87 (2003) 475-491
43. Rich S., and McLaughlin V.V. Endothelin receptor blockers in cardiovascular disease. Circulation 108 (2003) 2184
44. Teerlink J.R. The role of endothelin in the pathogenesis of heart failure. Curr Cardiol Rep 4 (2002) 206-212
45. Anand I., McMurray J., Cohn J.N., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
46. Kalra P.R., Moon J.C., and Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 85 (2002) 195-197
47. Luscher T.F., Enseleit F., Pacher R., et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106 (2002) 2666-2672
48. Spieker L.E., and Luscher T.F. Will endothelin receptor antagonists have a role in heart failure?. Med Clin North Am 87 (2003) 459-474
49. Staniloae C., Dupuis J., White M., et al. Reduced pulmonary clearance of endothelin in congestive heart failure: a marker of secondary pulmonary hypertension. J Card Fail 10 (2004) 427-432
50. von Lueder T.G., Kjekshus H., Edvardsen T., et al. Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1. Cardiovasc Res 63 (2004) 41-50
51. Rodeheffer R.J. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?. J Am Coll Cardiol 44 (2004) 740-749
52. D'Souza S.P., Davis M., and Baxter G.F. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 101 (2004) 113-129
53. Luchner A., and Schunkert H. Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res 63 (2004) 443-449
54. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50 (2004) 1503-1510
55. Luchner A., Stevens T.L., Borgeson D.D., et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274 (1998) H1684-H1689
56. Wang T.J., Larson M.G., Levy D., et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108 (2003) 13-16
57. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 (2004) 1328-1333
58. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
59. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
60. Young J.B., Correia N.G., Francis G.S., et al. Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: what are the nuances?. Cleve Clin J Med 71 Suppl 5 (2004) S1-S17
61. Tang W.H., Girod J.P., Lee M.J., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108 (2003) 2964-2966
62. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
63. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002) 920-926
64. Cheung B.M., Li C.Y., and Wong L.Y. Adrenomedullin: its role in the cardiovascular system. Semin Vasc Med 4 (2004) 129-134
65. Lainchbury J.G. Novel neurohumoral factors in congestive heart failure: adrenomedullin. Curr Cardiol Rep 3 (2001) 208-214
66. Kobayashi K., Kitamura K., Etoh T., et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 131 (1996) 994-998
67. Baumer A.T., Schumann C., Cremers B., et al. Gene expression of adrenomedullin in failing myocardium: comparison to atrial natriuretic peptide. J Appl Physiol 92 (2002) 1058-1063
68. Bunton D.C., Petrie M.C., Hillier C., et al. The clinical relevance of adrenomedullin: a promising profile?. Pharmacol Ther 103 (2004) 179-201
69. Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003) 1432-1439
70. Richards A.M., Nicholls M.G., Lainchbury J.G., et al. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
71. Bristow M.R., and Long C.S. Cardiotrophin-1 in heart failure. Circulation 106 (2002) 1430-1432
72. Bale T.L., Hoshijima M., Gu Y., et al. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 101 (2004) 3697-3702
73. Katsuragi N., Morishita R., Nakamura N., et al. Periostin as a novel factor responsible for ventricular dilation. Circulation 110 (2004) 1806-1813